

US00D996999S

(12)

United States Design Patent

Morelock

(10) Patent No.:

US D996,999 S

(45) Date of Patent:

** Aug. 29, 2023

(54)

WEARABLE SENSOR

Y10T 29/49117; A61N 1/0424; A61N 1/044; A61N 1/325; A61N 1/326; A61N 1/327; A61N 1/0476

See application file for complete search history.

(71)

Applicant: Biolinq Incorporated, San Diego, CA (US)

(72)

Inventor: David Michael Morelock, Escondido, CA (US)

(56)

References Cited

(73)

Assignee: Biolinq Incorporated, San Diego, CA (US)

U.S. PATENT DOCUMENTS

(**) Term:

15 Years

(21)

Appl. No.:

29/815,797

(22)

Filed:

Nov. 16, 2021

(51)

LOC (14) Cl.

24-01

(52)

U.S. Cl.

USPC D24/186; D10/81; D24/216

(58)

Field of Classification Search

USPC D10/78, 81; D24/108, 134, 186, 187, D24/216

CPC A61M 37/0015; A61M 25/00; A61M 2037/0023; A61M 2037/0046; A61M 2037/0053; A61M 37/00; A61M 2037/0007; A61M 2037/0061; A61M 2205/33; A61M 2205/3303; A61M 2210/04; A61M 2230/20; A61B 5/14503; A61B 5/14514; A61B 5/14532; A61B 5/14546; A61B 5/14865; A61B 5/1495; A61B 5/150022; A61B 5/150282; A61B 5/150427; A61B 5/150969; A61B 5/150984; A61B 5/4839; A61B 5/685; A61B 2562/028; A61B 2562/12; A61B 2562/125; A61B 2560/0242; A61B 2560/0266; A61B 2560/0271; A61B 2560/04; A61B 2560/0406; A61B 2560/0412; A61B 2562/16; A61B 2562/162; A61B 2562/164; A61B 2562/166; A61B 2562/168; A61B 2562/0271; A61B 2562/0272; A61B 5/0008; C12Q 1/006; G01N 27/3271;

4,305,401 A

12/1981

Reissmueller et al.

4,323,996 A

4/1982

Ganter

4,407,295 A

10/1983

Steuer et al.

5,131,390 A *

7/1992

Sakaguchi A61B 5/4261 600/573

5,279,543 A

1/1994

Glikfeld et al.

5,286,364 A

2/1994

Yacynych et al.

5,540,828 A

7/1996

Yacynych

5,730,714 A

3/1998

Guy et al.

5,766,132 A

6/1998

Yasukawa et al.

6,036,055 A

3/2000

Mogadam et al.

6,139,718 A

10/2000

Kurnik et al.

6,269,053 B1

7/2001

Kawata et al.

6,284,126 B1

9/2001

Kurnik et al.

6,413,396 B1

7/2002

Yang et al.

6,471,903 B2

10/2002

Sherman et al.

6,603,987 B2

8/2003

Whitson

6,814,845 B2

11/2004

Wilson et al.

6,862,466 B2

3/2005

Ackerman

6,908,453 B2 *

6/2005

Fleming A61B 5/14514 604/173

7,097,776 B2

8/2006

Govinda Raju

7,132,054 B1

11/2006

Kravitz et al.

7,262,068 B2

8/2007

Roy et al.

7,343,188 B2 *

3/2008

Sohrab A61B 5/150824 600/347

7,344,499 B1

3/2008

Prausnitz et al.

7,429,333 B2

9/2008

Chiou et al.

7,456,112 B2

11/2008

Lee

7,493,232 B1

2/2009

Surina

8,022,292 B2

9/2011

Arianpour et al.

8,088,321 B2

1/2012

Ferguson et al.

8,094,009 B2

1/2012

Allen et al.

8,125,331 B2

2/2012

Allen et al.

8,130,095 B2

3/2012

Allen et al.

8,284,046 B2

10/2012

Allen et al.

8,574,165 B2

11/2013

Marsh

8,798,799 B2

8/2014

Deo et al.

8,909,543 B2

12/2014

Tropper et al.

D722,697 S

2/2015

Moon et al.

D750,786 S

3/2016

Davies et al.

D757,000 S


5/2016

Lagomarsino et al.

9,551,698 B2

1/2017

Huys et al.



US D996,999 S

Page 2

9,737,247	B2	8/2017	Wang et al.	
9,743,870	B2	8/2017	Wang et al.	
D815,289	S	4/2018	Evers et al.	
D816,229	S	4/2018	Frick et al.	
9,933,387	B1	4/2018	McCanna et al.	
D820,988	S *	6/2018	Pushpala	A61N 1/0444 D24/169
10,092,207	B1	10/2018	Windmiller	
10,136,846	B2	11/2018	Wang et al.	
D842,996	S	3/2019	Frick et al.	
D845,289	S *	4/2019	Chuang	A61B 5/1473 D14/250
10,251,565	B2 *	4/2019	Chan	A61B 5/14551
D867,911	S *	11/2019	Alabdin	A61B 5/14551 D10/104.1
10,492,708	B1	12/2019	Windmiller	
D875,254	S *	2/2020	Cooke	A61B 5/7405 D24/169
D882,432	S *	4/2020	Yee	A61B 5/7405 D24/186
10,765,369	B2 *	9/2020	Antonio	A61B 5/1473
11,045,142	B1	6/2021	Windmiller et al.	
11,207,025	B1 *	12/2021	Trapero Martin ...	A61B 5/1102
11,406,818	B2	8/2022	Windmiller	
11,654,270	B2	5/2023	Mansfield et al.	
11,660,392	B2 *	5/2023	Kamen	A61M 5/14248 604/151
2003/0225360	A1 *	12/2003	Eppstein	A61N 1/044 604/19
2006/0015061	A1	1/2006	Kuo et al.	
2007/0170054	A2	7/2007	Wilsey	
2007/0213044	A1	9/2007	Steingart et al.	
2009/0088652	A1	4/2009	Tremblay	
2009/0143761	A1 *	6/2009	Cantor	A61N 1/0444 604/501
2009/0259118	A1	10/2009	Feldman et al.	
2010/0056873	A1	3/2010	Allen et al.	
2010/0286803	A1	11/2010	Tillotson et al.	
2012/0323097	A9	12/2012	Chowdhury	
2013/0065257	A1	3/2013	Wang et al.	
2013/0144131	A1	6/2013	Wang et al.	
2014/0259652	A1	9/2014	Pushpala et al.	
2014/0275897	A1 *	9/2014	Pushpala	A61B 5/150427 600/347
2014/0336487	A1	11/2014	Wang et al.	
2015/0335272	A1	11/2015	Natale et al.	
2017/0055851	A1	3/2017	Al-Ali	
2018/0249937	A1	9/2018	Wiese et al.	
2019/0095602	A1	3/2019	Setlak et al.	
2019/0125223	A1	5/2019	Wang et al.	
2019/0167167	A1	6/2019	Mitchell et al.	
2019/0309433	A1	10/2019	Sattayasamitsathit et al.	
2020/0085341	A1	3/2020	Windmiller	
2020/0101286	A1	4/2020	Windmiller et al.	
2020/0214566	A1	7/2020	Allen et al.	
2020/0254240	A1	8/2020	Windmiller et al.	
2020/0297997	A1	9/2020	Windmiller et al.	
2021/0187286	A1	6/2021	Windmiller et al.	
2021/0393201	A1	12/2021	Morelock et al.	
2022/0031209	A1	2/2022	Windmiller et al.	
2022/0031244	A1	2/2022	Windmiller et al.	
2022/0175278	A1	6/2022	Campbell et al.	
2022/0370011	A1	11/2022	Windmiller et al.	
2023/0074798	A1	3/2023	Tangney	
2023/0094419	A1	3/2023	Mansfield, III et al.	
2023/0099617	A1	3/2023	Mansfield, III et al.	
2023/0137258	A1	5/2023	Windmiller	

FOREIGN PATENT DOCUMENTS

CH	717520	A2	12/2021
EP	3871602	A1	9/2021
FR	3042872	B1	12/2020
JP	1721016	S	7/2022
WO	WO-2009034313	A2	3/2009
WO	WO-2009064164	A2	5/2009
WO	WO-2010120364	A2	10/2010
WO	WO-2012020332	A2	2/2012

WO	WO-2013058879	A2	4/2013
WO	WO-2020073060	A1	4/2020
WO	WO-2021148596	A1	7/2021
WO	WO-2023055755	A1	4/2023
WO	WO-2023064877	A1	4/2023

OTHER PUBLICATIONS

Abbot press release (2020). "New late-breaking data show use of Abbott's Freestyle® Libre System significantly reduces HBA1C levels in people with type 2 diabetes using insulin or not," 3 pages.

American Diabetes Association® Press Release (2020). "American Diabetes Association® Applauds policymakers' Focus on Addressing High Costs of Insulin for Seven Million Americans," 4 pages.

Bantle, J.P. et al. (1997). "Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid," J. Lab. Clin. Med. 130:436-441.

Beckles, G.L. et al. (2016). "Disparities in the prevalence of diagnosed diabetes—United States, 1999-2002 and 2011-2014," MMWR 65:1265-1269.

Biolinq, Inc. (2019). The Intelligent Continuous Glucose Monitoring System, 5 total pages.

Cao, J. et al. (2017). "Validation of capillary blood analysis and capillary testing mode on the epoc Point of Care system," Pract. Lab. Med. 9:24-27.

Castle, J.R. et al. (2012). "The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes," Diabetes Care 35:706-710.

Dexcom (2020). Analyst Day Presentation, 19 total pages.

Dexcom (2020). Analyst Day Presentation, 27 total pages.

Diabetes Care (2021). "7. Diabetes Technology: Standards of Medical Care in Diabetes—2021," Diabetes Care 44(Supplement 1):S85-S99.

Fang, M. et al. (2021). "Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018," N. Engl. Med. 384:2219-2228.

French, D.P. et al. (2008). "Original Article: Psychological Care Self-monitoring of blood glucose changed non-insulin-treated Type 2 diabetes patients' beliefs about diabetes and self-monitoring in a randomized trial," Diav. Med. 25:1218-1228.

Grady, M. et al. (2017). "Examining the Impact of a Novel Blood Glucose Monitor with Color Range Indicator on Decision-Making in Patients With Type 1 and Type 2 Diabetes and its Association With Patient Numeracy Level," JMIR Diabetes 2:e24.

Grady, M. et al. (2018). "Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients with Diabetes in Comparison to Blood Glucose Meters Without Color (Accents Study)," J. Diab. Sci. Tech. 12:1211-1219.

Groenendaal, W. et al. (2008). "Modeling Glucose and Water Dynamics in Human Skin," Diab. Tech. Therap. 10:283-293.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008). "Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes," N. Engl. Med. 359:1464-1476.

Karter, A.J. et al. (2021). "Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin—Treated Diabetes," JAMA 325:2273-2284.

Martens, T. et al. (2021). "Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin A Randomized Clinical Trial," JAMA 325:2262-2272.

McClatchey, P.M. et al. (2019). "Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays," Diabetes 68:1892-1901.

Neerken, S. et al. (2004). "Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography," J. Biomed. Optics 9:274-281.

Non-Final Office Action dated Nov. 14, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 10 pages.

Notice of Allowance dated Sep. 29, 2022, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 7 pages.

Notice of Allowance dated Jan. 25, 2023, for U.S. Appl. No. 29/774,399, filed Mar. 16, 2021, 11 pages.

Notice of Allowance dated Dec. 18, 2019, for U.S. Appl. No. 29/650,794, filed Jun. 8, 2018, 7 pages.

Notice of Allowance dated May 17, 2023, for U.S. Appl. No. 29/836,984, filed Apr. 29, 2022, 7 pages.

Polonsky, W.H. et al. (2011). "A survey of blood glucose monitoring in patients with type 2 diabetes: Are recommendations from health care professionals being followed?" *Curr. Med. Res. & Opinion* 27:31-37.

Rigla, M. et al. (2018). "Human Subcutaneous Tissue Response to Glucose Sensors: Macrophages Accumulation Impact on Sensor Accuracy," *Diabetes Technology & Therapeutics* 20:296-302.

Sheikh, Z. et al. (2015). "Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials," *Materials* 8:5671-5701.

Shi, T. et al. (2016). "Modeling and Measurement of Correlation between Blood and Interstitial Glucose Changes," *J. Diab. Res.* vol. 2016, 9 pages.

Al Hayek et al., "Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study" *Cureus* Oct. 27, 2020; 12(10):e11195. doi: 10.7759/cureus.11195.

Allen et al., "Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial" *Diabetes Res Clin Pract.* Jun. 2008 80(3): 371-379. doi:10.1016/j.diabres.2008.01.006.

Barrett et al., "Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years—United States, Mar. 1, 2020–Jun. 28, 2021" *MMWR Morb Mortal Wkly Rep.* Jan. 14, 2022; 71(2):59-65. doi: 10.15585/mmwr.mm7102e2. Centers for Disease Control, "National Diabetes Statistics Report 2020 Estimates of Diabetes and Its Burden in the United States" (2020) 32 pages.

Dunkin et al., "Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers" *Plast Reconstr Surg.* May 2007; 119(6):1722-1732. doi: 10.1097/01.prs.0000258829.07399.f0.

Ehrhardt et al., "The Effect of Real-Time Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Mellitus" *Journal of Diabetes Science and Technology* May 2011; 5(3):668-675.

Ehrhardt et al., "Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring" *Journal of Diabetes Science and Technology* Mar. 2019; 13(2):271-275.

Ehrhardt et al., "Continuous Glucose Monitoring As a Behavior Modification Tool" *Clin Diabetes.* Apr. 2020; 38(2):126-131. doi: 10.2337/cd19-0037.

Fonda et al., "The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes" *Journal of Diabetes Science and Technology* (2016) 10(4):898-904.

Han et al., "The End of the Road for the YSI 2300 Analyzer: Where Do We Go Now?" *Journal of Diabetes Science and Technology* (2020) 14(3):595-600.

Han et al., "The YSI 2300 Analyzer Replacement Meeting Report" *Journal of Diabetes Science and Technology* (2020) 14(3):679-686.

Sharifi et al., "Redundancy in Glucose Sensing: Enhanced Accuracy and Reliability of an Electrochemical Redundant Sensor for Continuous Glucose Monitoring" *Journal of Diabetes Science and Technology* (2016) 10(3):669-678.

Turner et al., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" *The Lancet* Sep. 1998; 352(9131):837-853.

Vigersky et al., "Short- and Long-Term Effects of Real-Time Continuous Glucose Monitoring in Patients with Type 2 Diabetes" *Diabetes Care* Jan. 2012; 35:32-38.

Wolicki et al., "Epidemiology and Prevention of Vaccine-Preventable Diseases: Chapter 6: Vaccine Administration" Centers for Disease Control and Prevention (2021) 17 pages.

World Health Organization, "Diabetes", Sep. 16, 2022, 5 pages.

Young et al., "Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial" *JAMA Intern Med.* Jul. 2017; 177(7):920-929.

* cited by examiner

Primary Examiner — Antoine Duval Davis

(74) *Attorney, Agent, or Firm* — Cooley LLP

(57)

CLAIM

The ornamental design for a wearable sensor, as shown and described.

DESCRIPTION

FIG. 1 is a front perspective view of a wearable sensor showing the new design;

FIG. 2 is a front view thereof;

FIG. 3 is a top plan view thereof;

FIG. 4 is a bottom plan view thereof;

FIG. 5 is a left side view thereof;

FIG. 6 is a right side view thereof;

FIG. 7 is a rear view thereof;

FIG. 8 is a front perspective view of another wearable sensor showing the new design;

FIG. 9 is a front view thereof;

FIG. 10 is a top plan view thereof;

FIG. 11 is a bottom plan view thereof;

FIG. 12 is a left side view thereof;

FIG. 13 is a right side view thereof;

FIG. 14 is a rear view thereof;

FIG. 15 is a front perspective view of another wearable sensor showing the new design;

FIG. 16 is a front view thereof;

FIG. 17 is a top plan view thereof;

FIG. 18 is a bottom plan view thereof;

FIG. 19 is a left side view thereof;

FIG. 20 is a right side view thereof;

FIG. 21 is a rear view thereof;

FIG. 22 is a front perspective view of another wearable sensor showing the new design;

FIG. 23 is a front view thereof;

FIG. 24 is a top plan view thereof;

FIG. 25 is a bottom plan view thereof;

FIG. 26 is a left side view thereof;

FIG. 27 is a right side view thereof;

FIG. 28 is a rear view thereof;

FIG. 29 is a front perspective view of another wearable sensor showing the new design;

FIG. 30 is a front view thereof;

FIG. 31 is a top plan view thereof;

FIG. 32 is a bottom plan view thereof;

FIG. 33 is a left side view thereof;

FIG. 34 is a right side view thereof;

FIG. 35 is a rear view thereof;

FIG. 36 is a front perspective view of another wearable sensor showing the new design;

FIG. 37 is a front view thereof;

FIG. 38 is a top plan view thereof;

FIG. 39 is a bottom plan view thereof;

FIG. 40 is a left side view thereof;

FIG. 41 is a right side view thereof;

FIG. 42 is a rear view thereof;

FIG. 43 is a front perspective view of another wearable sensor showing the new design;

FIG. 44 is a front view thereof;

FIG. **45** is a top plan view thereof;
FIG. **46** is a bottom plan view thereof;
FIG. **47** is a left side view thereof;
FIG. **48** is a right side view thereof; and,
FIG. **49** is a rear view thereof.

The broken lines are for the purpose of illustrating portions of the article and form no part of the claimed design.

1 Claim, 28 Drawing Sheets




FIG. 1




FIG. 2




FIG. 3




FIG. 4



FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11



FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49